Physician profile
Jesse S Hicks
NPI 1801939509
$1,107.45
in general payments reported to CMS, 2019-2025
10 companies · $668 in 2025
The $668 reported for 2025 was more than what 84% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $33.66 · 2021: $28.27 · 2022: $111 · 2023: $157 · 2024: $109 · 2025: $668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $934.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $934.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $292.78 | 2022-2025 | Oxervate |
| Biotissue Holdings INC. | $249.35 | 2024-2025 | |
| Tarsus Pharmaceuticals, INC. | $221.48 | 2025 | Xdemvy |
| Coopervision INC. | $212.35 | 2021-2025 | Myday Contact Lens, Clariti Contact Lens, Biofinity Contact Lens |
| Lombart Brothers, INC. | $31.42 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $23.89 | 2023 | |
| Alcon Vision LLC | $23.64 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Heidelberg Engineering, INC. | $17.21 | 2023 | Spectralis |
| Bausch & Lomb Americas INC. | $15.93 | 2024 | Miebo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Hicks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.